Dermatological Therapeutics: Global Markets

• Publication date: January 2009

INTRODUCTIONSTUDY GOALS AND OBJECTIVESBCC’s goal in conducting this study was to understand the current status of the U.S. dermatological therapeutics industry and to assess it in the medium term from 2008 through 2013. We were particularly interested in understanding the future market potential for the current and emerging technologies and products within the dermatological therapeutics industry. This report assesses the availa...

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC’s goal in conducting this study was to understand the current status of the U.S. dermatological therapeutics industry and to assess it in the medium term from 2008 through 2013. We were particularly interested in understanding the future market potential for the current and emerging technologies and products within the dermatological therapeutics industry. This report assesses the available therapeutic procedures for skin, along with the drugs and technologies currently being used for various skin treatments. The role of public agencies, the regulatory environment, and non-governmental stakeholders has also been examined.

REASONS FOR DOING THIS STUDY

Skin disorders have a high active as well as passive morbidity in most human populations across the world. Yet, most dermatology manufacturers and dermatologists rely on cosmetic applications and procedures for survival.

INTENDED AUDIENCE

This study is likely to be of interest to individuals and organizations involved in aspects of dermatological therapeutics industry, such as research, manufacturing and even large buyers in the industry. This report will also be of interest to manufacturers and marketers of dermatological therapeutics industry across the world.  
 

Global Pharmaceutical Industry

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THIS STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC RESEARCH REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: SUMMARY

SUMMARY TABLE GLOBAL DERMATOLOGICAL THERAPEUTICS REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013 ($ BILLIONS)

SUMMARY FIGURE GLOBAL DERMATOLOGICAL THERAPEUTICS REVENUE FORECAST BY MARKET SEGMENT, 2008 AND 2013 (%)

CHAPTER THREE: OVERVIEW

HUMAN SKIN

TABLE 1 FUNCTIONS OF THE SKIN

TABLE 1 (CONTINUED)

SKIN DISORDERS

TABLE 2 DISORDERS OF THE SKIN

TABLE 2 (CONTINUED)

TABLE 2 (CONTINUED)

TABLE 2 (CONTINUED)

ACNE

TABLE 3 TYPES OF ACNE

ROSACEA

TABLE 4 TYPES OF ROSACEA

TABLE 5 DRUGS AND THEIR ACTION AGAINST ACNE AND ROSACEA

BACTERIAL INFECTIONS OF THE SKIN

TABLE 6 TYPES OF BACTERIAL INFECTIONS OF THE SKIN

TABLE 6 (CONTINUED)

TABLE 6 (CONTINUED)

TABLE 7 SOME PRESCRIPTION DRUGS PRESCRIBED TO TREAT BACTERIAL SKIN INFECTIONS

TABLE 7 (CONTINUED)

TABLE 7 (CONTINUED)

BENIGN SKIN GROWTHS OR TUMORS

TABLE 8 TYPES OF BENIGN SKIN GROWTHS OR TUMORS

TABLE 8 (CONTINUED)

TABLE 9 SOME PRESCRIPTION DRUGS USED TO TREAT BENIGN SKIN GROWTHS

TABLE 9 (CONTINUED)

BULLOUS DISORDERS OR BLISTERING DISEASES

TABLE 10 TYPES OF BULLOUS DISORDERS

TABLE 10 (CONTINUED)

TABLE 11 SOME PRESCRIPTION DRUGS USED TO TREAT BULLOUS SKIN DISORDERS

TABLE 11 (CONTINUED)

SKIN CANCERS

TABLE 12 TYPES OF SKIN CANCERS

TABLE 12 (CONTINUED)

Types of Melanoma

Lentigo Maligna Melanoma

Superficial Spreading Melanoma

Nodular Melanoma

Acral-Lentiginous Melanoma

TABLE 13 SKIN CANCER INCIDENCE IN THE U.S

TABLE 14 SOME PRESCRIPTION DRUGS USED TO TREAT CUTANEOUS CARCINOMAS

CORNIFICATION DISORDERS

Calluses and Corns

TABLE 15 TYPES OF CALLUSES AND CORNS

Ichthyosis or Dry Skin

TABLE 16 TYPES OF ICHTHYOSIS

TABLE 16 (CONTINUED)

Keratosis Pilaris

TABLE 17 TYPES OF KERATOSIS PILARIS

Sebaceous Cysts

Dermatitis

TABLE 18 TYPES OF DERMATITIS

TABLE 18 (CONTINUED)

TABLE 19 SOME DRUGS PRESCRIBED FOR DERMATITIS

Fungal Infections of the Skin

TABLE 20 TYPES OF FUNGAL INFECTIONS OF THE SKIN

TABLE 20 (CONTINUED)

TABLE 21 SOME DRUGS PRESCRIBED TO TREAT FUNGAL INFECTIONS OF THE SKIN

TABLE 21 (CONTINUED)

HYPERSENSITIVITY AND INFLAMMATORY DISORDERS

Acute Febrile Neutrophilic Dermatosis (Sweet’s Syndrome)

Drug Eruptions and Reactions

TABLE 22 TYPES OF DRUG REACTIONS AND TYPICAL CAUSATIVE AGENTS

TABLE 22 (CONTINUED)

Erythema Multiforme

TABLE 23 TYPES OF ERYTHEMA MULTIFORME

Erythema Nodosum

Granuloma Annulare

Panniculitis

Pyoderma Gangrenosum

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Bed Sore

Pityriasis Rosea

TABLE 24 SOME DRUGS PRESCRIBED TO TREAT HYPERSENSITIVITY AND INFLAMMATORY DISORDERS

TABLE 24 (CONTINUED)

PARASITIC INFECTIONS OF THE SKIN

TABLE 25 TYPES OF PARASITIC INFECTION OF THE SKIN

TABLE 25 (CONTINUED)

TABLE 26 SOME DRUGS PRESCRIBED TO TREAT PARASITIC INFECTIONS OF THE SKIN

PSORIASIS AND SCALING DISEASES

TABLE 27 TYPES OF PSORIASIS AND SCALING DISEASES

Psoriasis Treatment

PIGMENTATION DISORDERS

TABLE 28 TYPES OF PIGMENTATION DISORDERS

Birthmarks

Poison Ivy

TABLE 29 SOME PRESCRIPTION DRUGS FOR PIGMENTATION DISORDERS

REACTIONS TO SUNLIGHT

Aging

Actinic Keratoses

Skin Cancers

Photosensitivity

TABLE 30 TYPES OF PHOTOSENSITIVITY

Sunburn

SWEATING DISORDERS

TABLE 31 TYPES OF SWEATING DISORDERS

VIRAL SKIN DISEASES

TABLE 32 TYPES OF VIRAL SKIN DISEASES

TABLE 32 (CONTINUED)

TABLE 33 SOME DRUGS PRESCRIBED TO TREAT VIRAL DISEASES OF THE SKIN

TABLE 33 (CONTINUED)

COMMON DIAGNOSTIC TESTS FOR SKIN DISORDERS

DERMOSCOPY

PATCH TESTING

SKIN BIOPSY

CULTURE

PHOTOTESTS

MORBIDITY/PREVALENCE

TABLE 34 SKIN DISORDER MORBIDITY IN THE U.S. BY AGE AND CAUSE (THOUSANDS)

THERAPEUTIC PROCEDURES FOR THE SKIN

CANCER SURGERY

Excisional Biopsy to Remove Skin Cancer

Curettage and Electrocautery

Mohs Micrographic Surgery (MMS)

Wide Local Excision

Skin Grafting

Lymph Node Removal

CHEMICAL PEELS

CRYOTHERAPY/CRYOSURGERY

Ice Packs

Cold Gel Packs

Ice Immersion

Ice Massage

Vapocoolant Sprays

RADIOTHERAPY

CHEMOTHERAPY

Chemotherapy Creams

Chemotherapy into a Vein

LASER SURGERY

TABLE 35 SKIN CONDITIONS REQUIRING ONLY LASER SURGERY

TABLE 35 (CONTINUED)

TABLE 35 (CONTINUED)

Carbon Dioxide Laser

YAG Laser

Pulsed Dye Laser or Argon Laser

Excimer Laser

TABLE 36 ADVANTAGES AND DISADVANTAGES OF EXCIMER LASER

PHOTODYNAMIC THERAPY

TABLE 37 VARIOUS CANCERS TREATABLE BY PDT

Application in Dermatology

TABLE 38 VARIOUS SKIN DISORDERS TREATABLE BY PDT

Goeckerman Treatment

PUVA

Ultraviolet B Phototherapy

Broadband

Narrowband

TABLE 39 ADVANTAGES AND DISADVANTAGES OF UVB THERAPY

SCLEROTHERAPY

CHAPTER FOUR: PRESCRIPTION DERMATOLOGICAL DRUGS

SYSTEMIC DRUGS

ACITRETIN

CLINDAMYCIN

ERYTHROMYCIN

CYCLOSPORINE

TABLE 40 ADVANTAGES AND DISADVANTAGES OF CYCLOSPORINE

METHOTREXATE

TABLE 41 ADVANTAGES AND DISADVANTAGES OF METHOTREXATE

THALIDOMIDE

SYSTEMIC ANTIBACTERIAL AGENTS

Antileprotic Drugs (Including Dapsone)

Antimalarial Drugs (Including Hydroxychloroquine)

SYSTEMIC ANTIFUNGAL AGENTS

SYSTEMIC ANTIHISTAMINES

SYSTEMIC ANTIPARASITIC AGENTS

SYSTEMIC ANTIPRURITIC AGENTS

SYSTEMIC ANTIVIRAL AGENTS

SYSTEMIC CORTICOSTEROIDS

SYSTEMIC INTERFERONS

SYSTEMIC RETINOID

OTHER SYSTEMIC DRUGS

6-Thioguanine

Hydroxyurea

Mycophenolate Mofetil

Sulfasalazine

BIOLOGICAL THERAPIES (BIOLOGICS)

Colchicine

CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS

Retinoids

Hormones and Anti-Androgens

Hormones and … (Continued)

TOPICAL TREATMENTS

ACICLOVIR

TOPICAL RETINOIDS

ANTHRALIN

TABLE 42 ADVANTAGES AND DISADVANTAGES OF ANTHRALIN

COAL TAR

TABLE 43 ADVANTAGES AND DISADVANTAGES OF COAL TAR

CORTICOSTEROIDS

TABLE 44 ADVANTAGES AND DISADVANTAGES OF CORTICOSTEROIDS

TABLE 45 TOPICAL CORTICOSTEROIDS, 2004

TABLE 45 (CONTINUED)

TABLE 45 (CONTINUED)

RETINOID: TAZAROTENE

TABLE 46 ADVANTAGES AND DISADVANTAGES OF TAZAROTENE

VITAMIN D3: CALCIPOTRIENE

TABLE 47 ADVANTAGES AND DISADVANTAGES OF CALCIPOTRIOL

CAPSAICIN

TOPICAL MEDICATIONS IN CLINICAL TRIALS

MOISTURIZERS AND SCALE REMOVERS

TABLE 48 DRUG TREATMENTS FOR SKIN DISEASE INTRODUCED IN 2006

TABLE 48 (CONTINUED)

TABLE 48 (CONTINUED)

TABLE 48 (CONTINUED)

TABLE 48 (CONTINUED)

TABLE 48 (CONTINUED)

CHAPTER FIVE: TECHNOLOGY REVIEW

EMERGING TECHNOLOGIES IN DERMATOLOGY

DNA MICROARRAY TECHNOLOGY IN DERMATOLOGY

ADVANCES IN THE TREATMENT OF VARICOSE VEINS

EMERGING TREATMENT OF ATOPIC DERMATITIS

EMERGING DRUGS FOR ICHTHYOSIS

PROGRESS IN THE MANAGEMENT OF ACNE

PLASMA SKIN REGENERATION TECHNOLOGY

TABLE 49 NEW TECHNOLOGIES IN DERMATOLOGY

TABLE 49 (CONTINUED)

PERMEATION ENHANCEMENT TECHNOLOGIES

Drug Permeation Enhancement via Buccal Route

Thiomatrix: Permeation Enhancement

Merrion’s Technology: Gastrointestinal Permeation Enhancement Technology (GIPET)

FIGURE 1 GASTROINTESTINAL PERMEATION ENHANCEMENT TECHNOLOGY

Transdermal Protein Delivery or Measurement Using Low-Frequency Sonophoresis

RADIOTHERAPY

External Radiotherapy

Conformal Radiotherapy

Intensity Modulated Radiotherapy

Internal Radiotherapy

Radioactive Implants

Radioactive Liquids

Radioactive … (Continued)

PLASMA SKIN REGENERATION

Plasma Skin … (Continued)

Plasma Skin … (Continued)

CHAPTER SIX: PATENT ANALYSIS

PATENT ISSUE TRENDS IN UNITED STATES

FIGURE 2 U.S. PATENT TRENDS, 1990-2001

TABLE 50 NUMBER OF U.S. PATENTS ISSUED, 2003 TO JULY 31, 2008

TABLE 51 COMPANIES AND NUMBER OF U.S. PATENTS FILED BY THEM, 2003 TO JULY 31, 2008

TABLE 52 RECENT DERMATOLOGY U.S. PATENTS

TABLE 52 (CONTINUED)

TABLE 52 (CONTINUED)

TABLE 52 (CONTINUED)

PATENT ISSUE TRENDS IN EUROPE

TABLE 53 EUROPEAN DERMATOLOGICAL PATENTS, 2003-JULY 2008.

TABLE 54 RECENT PATENTS ISSUED BY THE EPO

TABLE 54 (CONTINUED)

CHAPTER SEVEN: INDUSTRY PARTICIPANT PROFILES

MANUFACTURERS OF DERMATOLOGICAL DRUGS

AGI DERMATICS

ALLERGAN, INC

AMGEN, INC

ANACOR PHARMACEUTICALS

ANIKA THERAPEUTICS, INC

ASTELLAS US, LLC

CHESTER VALLEY PHARMACEUTICALS, INC

CORIA LABORATORIES, LTD

CORIA LABORATORIES, LTD

DERMIK LABORATORIES, INC

DUSA PHARMACEUTICALS, INC.

EISAI, INC.

FERNDALE LABORATORIES, INC.

GALDERMA LABORATORIES

GENENTECH, INC.

ISOLAGEN, INC.

LEO PHARMA A/S

MEDICIS PHARMACEUTICAL CORP

MEDIMETRIKS PHARMACEUTICALS, INC.

MERZ PHARMA UK, LTD.

NEOSIL, INC.

NYCOMED U.S., INC.

OBAGI MEDICAL PRODUCTS, INC.

ONSET THERAPEUTICS

ORTHONEUTROGENA

PIERRE FABRE PHARMACEUTICALS, INC

PRIME PHARMACEUTICALS CORP

QLT, INC.

QUINNOVA PHARMACEUTICALS

SCHERING-PLOUGH CORP

SINCLAIR PHARMACEUTICALS

SKINMEDICA, INC.

STIEFEL LABORATORIES, INC.

SUMMERS LABORATORIES, INC

SYNTOPIX GROUP, PLC

TRIAX PHARMACEUTICALS, LLC

VALEANT PHARMACEUTICALS INTERNATIONAL

VALEO PHARMA, INC.

WARNER CHILCOTT, LTD

XOMA, LTD

NON-COMMERCIAL ORGANIZATIONS

AFRICAN ASSOCIATION OF DERMATOLOGY

AMERICAN ACADEMY OF DERMATOLOGY (AAD)

AMERICAN BEHCET’S DISEASE ASSOC., INC

AMERICAN CELIAC SOCIETY

AMERICAN HEMOCHROMATOSIS SOCIETY, INC

AMERICAN LUPUS SOCIETY

AMERICAN SKIN ASSOCIATION, INC

AMERICAN SOCIAL HEALTH ASSOC

ARTHRITIS FOUNDATION

ASIAN DERMATOLOGICAL ASSOCIATION

ASSOCIATION OF PROFESSORS OF DERMATOLOGY

ATAXIA-TELANGIECTASIA CHILDREN’S PROJECT

BASAL CELL CARCINOMA NEVUS SYNDROME/GORLIN SYNDROME

BAY AREA LUPUS FOUNDATION

BLOOM’S SYNDROME REGISTRY

BRITISH ASSOCIATION OF DERMATOLOGISTS

CELIAC DISEASE FOUNDATION

CELIAC SPRUE ASSOCIATION/USA

CICATRICIAL ALOPECIA RESEARCH FOUNDATION

COALITION OF SKIN DISEASES

CORNELIA DE LANGE SYNDROME FOUNDATION, INC

CUTANEOUS LYMPHOMA FOUNDATION

DERMATOLOGY FOUNDATION

DERMATOLOGY NURSES ASSOCIATION (DNA)

DERMATOPATHOLOGY FOUNDATION

DYSAUTONOMIA FOUNDATION, INC

DYSTROPHIC EPIDERMOLYSIS BULLOSA

THE ECTODERMAL DYSPLASIA SOCIETY

EHLERS DANLOS NATIONAL FOUNDATION (EDNF)

EHLERS-DANLOS SYNDROME FOUNDATION

EUROPEAN ACADEMY FOR DERMATOLOGY AND VENEREOLOGY

EADV Administrative Office

THE EUROPEAN DERMATOLOGY FORUM

EUROPEAN SOCIETY FOR DERMATOLOGICAL RESEARCH

EUROPEAN UNION OF MEDICAL SPECIALISTS

FOUNDATION FOR ICHTHYOSIS AND RELATED SKIN TYPES

(F.I.R.S.T.)

GLUTEN INTOLERANCE GROUP (DERMATITIS HERPETIFORMIS)

HEMOCHROMATOSIS RESEARCH FOUNDATION

HIDRADENITIS SUPPURATIVA FOUNDATION, INC

HISTIOCYTOSIS ASSOCIATION OF AMERICA

INFLAMMATORY SKIN DISEASE INSTITUTE (ISDI)

INTERNATIONAL FOUNDATION FOR DERMATOLOGY

THE INTERNATIONAL LEAGUE OF DERMATOLOGICAL SOCIETIES OFFICE

INTERNATIONAL PEMPHIGUS PEMPHIGOID FOUNDATION

THE INTERNATIONAL SOCIETY OF DERMATOPATHOLOGY

KLIPPEL-TRENAUNAY SUPPORT GROUP

LUPUS FOUNDATION OF AMERICA, INC.

LYMPHOMA RESEARCH FOUNDATION

LYMPHOMATOID PAPULOSIS CENTRAL REGISTRY

MARFAN ASSOC. U.K.

THE MELANOMA RESEARCH FOUNDATION

MUSCULAR DYSTROPHY ASSOC

MYOSITIS ASSOCIATION OF AMERICA (MAA)

NATIONAL ALOPECIA AREATA FOUNDATION (NAAF)

NATIONAL ATAXIA FOUNDATION

NATIONAL ECZEMA ASSOCIATION (NEA)

NATIONAL ECZEMA ASSOCIATION FOR SCIENCE AND EDUCATION

NATIONAL ECZEMA SOCIETY

NATIONAL EPIDERMOLYSIS BULLOSA REGISTRY

NATIONAL FOUNDATION FOR ECTODERMAL DYSPLASIAS

NATIONAL FOUNDATION FOR VITILIGO AND PIGMENT DISORDERS

NATIONAL INCONITENTIA PIGMENTI FOUNDATION

NATIONAL MEDICAL ASSOC

NATIONAL NEUROFIBROMATOSIS FOUNDATION

NATIONAL ORGANIZATION FOR ALBINISM AND HYPOPIGMENTATION (NOAH)

NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD)

THE NATIONAL PEMPHIGUS FOUNDATION

NATIONAL PSORIASIS FOUNDATION

NATIONAL REGISTRY FOR ICHTHYOSIS AND RELATED DISORDERS

NATIONAL VITILIGO FOUNDATION

NEVOID BASAL CELL CARCINOMA SYNDROME SUPPORT NETWORK

PACHYONYCHIA CONGENITA PROJECT

THE PSORIASIS ASSOC.

SCLERODERMA FEDERATION, INC

SCLERODERMA FOUNDATION

SCLERODERMA RESEARCH FOUNDATION

THE SCLERODERMA SOCIETY

SOCIETY FOR INVESTIGATIVE DERMATOLOGY (SID)

SOCIETY FOR PEDIATRIC DERMATOLOGY (SPD)

THE STURGE-WEBER FOUNDATION

THE VITILIGO SOCIETY, U.K.

VITILIGO SUPPORT INTERNATIONAL

VZV RESEARCH FOUNDATION

XERODERMA PIGMENTOSUM SOCIETY

TABLE 55 DERMATOLOGICAL ASSOCIATIONS

TABLE 55 (CONTINUED)

STRATEGIC ALLIANCES IN THE DERMATOLOGY MARKET

MERGERS & ACQUISITIONS

TABLE 56 SIGNIFICANT MERGERS AND ACQUISITIONS (2005-2008)

TABLE 56 (CONTINUED)

TABLE 56 (CONTINUED)

VENTURE CAPITAL DEALS

CHAPTER EIGHT: REGULATORY PREVIEW

DRUG REGULATION IN THE UNITED STATES

LICENSES FOR MEDICAL DEVICES

DRUG REGULATION IN THE UNITED KINGDOM

LICENSES FOR DRUGS

DRUG AND EQUIPMENT APPROVAL IN EUROPE

LICENSES FOR MEDICAL EQUIPMENT

REIMBURSEMENT FOR DERMATOLOGICAL TREATMENT

REIMBURSEMENT IN THE UNITED STATES

REIMBURSEMENT IN EUROPE

Reimbursement in Europe (Continued)

CHAPTER NINE: MARKET METRICS

MARKET TRENDS

BIG PHARMA’S FOCUS ON BLOCKBUSTER DRUGS ENABLES SPECIALTY FOCUS BY SMALL AND MEDIUM-SIZED FIRMS

COSMETIC/AESTHETIC DERMATOLOGY FACES DOWNTURN

CHANGES IN REIMBURSEMENT AND OTHER LEGISLATION ARE CREATING UNCERTAINTY

Managed Care Issues

Medical Liability

Physician Quality Reporting Initiative (PQRI)

Dermatologic Surgery

Cosmetic Procedure Tax

INCREASED USE OF GENERICS IN PRESCRIPTION DERMATOLOGY

DIFFICULTIES IN DETERMINATION OF BIOAVAILABILITY OF TOPICAL DRUGS

PHYSICIAN SHORTAGE AND PARAMEDIC INFLUX IN DERMATOLOGY

CERTIFICATION EXAM FOR NURSE PRACTITIONERS IN DERMATOLOGY NOW AVAILABLE

USE OF PROCEDURE-THERAPY AND SPECIFIC DRUGS IN DERMATOLOGY

POLLUTION CONTRIBUTES TO RISE IN ATOPIC DERMATITIS

MANUFACTURERS OF TNF-BLOCKER DRUGS ORDERED TO HIGHLIGHT RISK OF FUNGAL INFECTIONS

HIGHER CO-PAYS FOR BIOLOGICS IMPACTS PRESCRIPTIONS

U.S. DERMATOLOGICAL MARKET

TABLE 57 LEADING DRUGS PRESCRIBED BY OFFICE-BASED DERMATOLOGISTS—ALL INDICATIONS, 2008 (THOUSANDS)

PRESCRIPTION DATA FOR ACNE

Prescription Data for Acne (Continued)

FIGURE 3 PRESCRIBING OF ORAL ANTIBIOTICS FOR THE INTITIAL TREATMENT OF ACNE: CURRENT AND IN 1 YEAR (N=75)

FIGURE 4 PRESCRIBING OF TOPICAL ANTIBIOTICS/RETINOIDS FOR ACNE: CURRENT AND IN 1 YEAR (N=75)

TABLE 58 U.S. DERMATOLOGICAL THERAPEUTICS MARKET: REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013 ($BILLIONS)

FIGURE 5 SHARE OF SEGMENTS IN U.S. PRESCRIPTION DERMATOLOGY MARKET, 2008 AND 2013 (%)

FIGURE 5 (CONTINUED)

FIGURE 6 LEADING PRESCRIPTION DRUG REVENUES IN GLOBAL DERMATOLOGY MARKET, 2008 ($ MILLIONS)

FIGURE 6 (CONTINUED)

ENBREL

FIGURE 7 ENBREL SALES IN GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (%, TOTAL REVENUE = $ 3,230 MILLION)

BOTOX

FIGURE 8 BOTOX SALES IN THE GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (%, TOTAL REVENUE = $ 1,200 MILLION

FIGURE 8 (CONTINUED)

LOCERYL

FIGURE 9 LOCERYL SALES IN GLOBAL DERMATOLOGY MARKET BY GEOGRAPHY, 2008 (%, TOTAL = $350 MILLION

FIGURE 10 GLOBAL DERMATOLOGICAL PRESCRIPTION MARKET BY REGIONAL SHARE—FUTURE OUTLOOK, 2011 (%)

TABLE 59 MARKET SHARE OF PRESCRIPTION DRUG MANUFACTURERS, 2005-2007 ($ MILLIONS)

GLOBAL DERMATOLOGICAL THERAPEUTICS MARKET

FIGURE 11 GLOBAL DERMATOLOGICAL MARKET BY REGIONAL SHARE, 2008 (%)

TABLE 60 GLOBAL DERMATOLOGICAL THERAPEUTICS REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013

FIGURE 12 GLOBAL PRESCRIPTION DERMATOLOGY MARKET SHARE BY SEGMENT, 2008 (%)

FIGURE 12 (CONTINUED)

GLOBAL DERMATOLOGICAL … (CONTINUED)

GLOBAL DERMATOLOGICAL … (CONTINUED)

LIST OF TABLES

SUMMARY TABLE GLOBAL DERMATOLOGICAL THERAPEUTICS

REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013

($ BILLIONS)

TABLE 1 FUNCTIONS OF THE SKIN

TABLE 2 DISORDERS OF THE SKIN

TABLE 3 TYPES OF ACNE

TABLE 4 TYPES OF ROSACEA

TABLE 5 DRUGS AND THEIR ACTION AGAINST ACNE AND ROSACEA

TABLE 6 TYPES OF BACTERIAL INFECTIONS OF THE SKIN

TABLE 7 SOME PRESCRIPTION DRUGS PRESCRIBED TO

TREAT BACTERIAL SKIN INFECTIONS

TABLE 8 TYPES OF BENIGN SKIN GROWTHS OR TUMORS

TABLE 9 SOME PRESCRIPTION DRUGS USED TO TREAT

BENIGN SKIN GROWTHS

TABLE 10 TYPES OF BULLOUS DISORDERS

TABLE 11 SOME PRESCRIPTION DRUGS USED TO TREAT

BULLOUS SKIN DISORDERS

TABLE 12 TYPES OF SKIN CANCERS

TABLE 13 SKIN CANCER INCIDENCE IN THE U.S.

TABLE 14 SOME PRESCRIPTION DRUGS USED TO TREAT

CUTANEOUS CARCINOMAS

TABLE 15 TYPES OF CALLUSES AND CORNS

TABLE 16 TYPES OF ICHTHYOSIS

TABLE 17 TYPES OF KERATOSIS PILARIS

TABLE 18 TYPES OF DERMATITIS

TABLE 19 SOME DRUGS PRESCRIBED FOR DERMATITIS

TABLE 20 TYPES OF FUNGAL INFECTIONS OF THE SKIN

TABLE 21 SOME DRUGS PRESCRIBED TO TREAT FUNGAL

INFECTIONS OF THE SKIN

TABLE 22 TYPES OF DRUG REACTIONS AND TYPICAL

CAUSATIVE AGENTS

TABLE 23 TYPES OF ERYTHEMA MULTIFORME

TABLE 24 SOME DRUGS PRESCRIBED TO TREAT

HYPERSENSITIVITY AND INFLAMMATORY DISORDERS

TABLE 25 TYPES OF PARASITIC INFECTION OF THE SKIN

TABLE 26 SOME DRUGS PRESCRIBED TO TREAT PARASITIC

INFECTIONS OF THE SKIN

TABLE 27 TYPES OF PSORIASIS AND SCALING DISEASES

TABLE 28 TYPES OF PIGMENTATION DISORDERS

TABLE 29 SOME PRESCRIPTION DRUGS FOR PIGMENTATION

DISORDERS

TABLE 30 TYPES OF PHOTOSENSITIVITY

TABLE 31 TYPES OF SWEATING DISORDERS

TABLE 32 TYPES OF VIRAL SKIN DISEASES

TABLE 33 SOME DRUGS PRESCRIBED TO TREAT VIRAL DISEASES OF

THE SKIN

TABLE 34 SKIN DISORDER MORBIDITY IN THE U.S. BY AGE AND

CAUSE (THOUSANDS)

TABLE 35 SKIN CONDITIONS REQUIRING ONLY LASER SURGERY

TABLE 36 ADVANTAGES AND DISADVANTAGES OF EXCIMER LASER

TABLE 37 VARIOUS CANCERS TREATABLE BY PDT

TABLE 38 VARIOUS SKIN DISORDERS TREATABLE BY PDT

TABLE 39 ADVANTAGES AND DISADVANTAGES OF UVB THERAPY

TABLE 40 ADVANTAGES AND DISADVANTAGES OF CYCLOSPORINE

TABLE 41 ADVANTAGES AND DISADVANTAGES OF METHOTREXATE

TABLE 42 ADVANTAGES AND DISADVANTAGES OF ANTHRALIN

TABLE 43 ADVANTAGES AND DISADVANTAGES OF COAL TAR

TABLE 44 ADVANTAGES AND DISADVANTAGES OF

CORTICOSTEROIDS

TABLE 45 TOPICAL CORTICOSTEROIDS, 2004

TABLE 46 ADVANTAGES AND DISADVANTAGES OF

TAZAROTENE

TABLE 47 ADVANTAGES AND DISADVANTAGES OF CALCIPOTRIOL

TABLE 48 DRUG TREATMENTS FOR SKIN DISEASE

INTRODUCED IN 2006

TABLE 49 NEW TECHNOLOGIES IN DERMATOLOGY

TABLE 50 NUMBER OF U.S. PATENTS ISSUED, 2003 TO

JULY 31, 2008

TABLE 51 COMPANIES AND NUMBER OF U.S. PATENTS FILED BY

THEM, 2003 TO JULY 31, 2008

TABLE 52 RECENT DERMATOLOGY U.S. PATENTS

TABLE 53 EUROPEAN DERMATOLOGICAL PATENTS, 2003-JULY 2008

TABLE 54 RECENT PATENTS ISSUED BY THE EPO

TABLE 55 DERMATOLOGICAL ASSOCIATIONS

TABLE 56 SIGNIFICANT MERGERS AND ACQUISITIONS (2005-2008)

TABLE 57 LEADING DRUGS PRESCRIBED BY OFFICE-BASED

DERMATOLOGISTS—ALL INDICATIONS, 2008 (THOUSANDS)

TABLE 58 U.S. DERMATOLOGICAL THERAPEUTICS MARKET:

REVENUE FORECAST BY MARKET SEGMENT, THROUGH 2013

($ BILLIONS)

TABLE 59 MARKET SHARE OF PRESCRIPTION DRUG

MANUFACTURERS, 2005-2007 ($ MILLIONS)

TABLE 60 GLOBAL DERMATOLOGICAL THERAPEUTICS REVENUE

FORECAST BY MARKET SEGMENT, THROUGH 2013

LIST OF FIGURES

SUMMARY FIGURE GLOBAL DERMATOLOGICAL THERAPEUTICS

REVENUE FORECAST BY MARKET SEGMENT, 2008 AND 2013 (%)

FIGURE 1 GASTROINTESTINAL PERMEATION ENHANCEMENT

TECHNOLOGY

FIGURE 2 U.S. PATENT TRENDS, 1990-2001

FIGURE 3 PRESCRIBING OF ORAL ANTIBIOTICS FOR THE INTITIAL

TREATMENT OF ACNE: CURRENT AND IN 1 YEAR (N=75)

FIGURE 4 PRESCRIBING OF TOPICAL ANTIBIOTICS/RETINOIDS FOR

ACNE: CURRENT AND IN 1 YEAR (N=75)

FIGURE 5 SHARE OF SEGMENTS IN U.S. PRESCRIPTION

DERMATOLOGY MARKET, 2008 AND 2013 (%)

FIGURE 6 LEADING PRESCRIPTION DRUG REVENUES IN GLOBAL

DERMATOLOGY MARKET, 2008 ($ MILLIONS)

FIGURE 7 ENBREL SALES IN GLOBAL DERMATOLOGY MARKET BY

GEOGRAPHY, 2008 (%, TOTAL REVENUE = $ 3,230 MILLION)

FIGURE 8 BOTOX SALES IN THE GLOBAL DERMATOLOGY MARKET

BY GEOGRAPHY, 2008 (%, TOTAL REVENUE = $ 1,200 MILLION

FIGURE 9 LOCERYL SALES IN GLOBAL DERMATOLOGY MARKET BY

GEOGRAPHY, 2008 (%, TOTAL = $350 MILLION

FIGURE 10 GLOBAL DERMATOLOGICAL PRESCRIPTION MARKET BY

REGIONAL SHARE—FUTURE OUTLOOK, 2011 (%)

FIGURE 11 GLOBAL DERMATOLOGICAL MARKET BY REGIONAL

SHARE, 2008 (%)

FIGURE 12 GLOBAL PRESCRIPTION DERMATOLOGY MARKET SHARE

BY SEGMENT, 2008 (%)

Pharmaceutical in World

Cuba Poisonings, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Cuba, World

Fiji Poisonings, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Fiji, World

Cook Islands Poisonings, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : World

Iran Poisonings, 30-44 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : Iran, World

Saint Vincent Poisonings, 15-29 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : World